Karyopharm Therapeutics (KPTI) Tops Q3 EPS by 2c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.85), $0.02 better than the analyst estimate of ($0.87).

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy
• Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight